Particle Sciences Expands Biopharmaceutical Development Infrastructure
BETHLEHEM, Pa., July 15, 2014 /PRNewswire/ -- Particle Sciences, Inc. has expanded its development capabilities to accommodate the increasing demand for biopharmaceutical formulation and analysis. According to Robert Becker, Vice President Biopharmaceutical Sales and Business Development at Particle Sciences, "Our company has been working with biologics for some time, accumulating significant infrastructure and intellectual property. We regularly work with biopharmaceuticals and vaccines ranging from therapeutic proteins, including monoclonal antibodies, to nucleotides, to vaccine antigens and immunomodulators. Adding cell culture and extensive instrumentation to support the testing and characterizations of these biopharmaceuticals was planned for later this year but we've accelerated implementation to meet our client's needs." With this most recent expansion, Particle Sciences can now run the full gambit of testing including, among others, ELISA, SDS-PAGE, Western blots, image analysis, HPLC, HPLC-MS, ligand-receptor binding assays, cellular proliferation, cytotoxicity and cellular activation assays.
Mark Mitchnick, Particle Sciences' CEO added, "This expansion augments our existing formulation and sterile manufacturing offerings. With our unique approach to biopharmaceutical formulation and the ability to quickly take our clients into the clinic, Particle Sciences anticipates becoming a leader in large molecule formulation and clinical trial supply." The company sees a rapidly growing industrial need for these services as biopharmaceutical and biosimilar products become an increasingly important component to the health care products market. Particle Sciences' formulation portfolio enables the broader, more efficient development and application of biopharmaceuticals, and can differentiate products in the biosimilars field.
Particle Sciences is an integrated provider of drug development services. Particle Sciences focuses on BCS II/III/IV molecules, biologics and highly potent compounds through a variety of technologies including emulsions, gels, micro and nano-particulates, drug/device combination products, solid solutions and others. Through a full range of formulation, analytic, and manufacturing services, Particle Sciences provides pharmaceutical companies with a complete and seamless development solution that minimizes the time and risk between discovery and the clinic. We also have an extensive history in government contracting alongside our clients. The company was founded in 1991 and is headquartered in Bethlehem, Pennsylvania. Visit www.particlesciences.com, email info@particlesciences.com or contact us at (610) 861- 4701 for information.
Contact: Maureen Grieco
Maureen.grieco@particlesciences.com
SOURCE Particle Sciences